-
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE)
-
Litifilimab was recently granted Breakthrough Therapy Designation by the FDA for CLE; AMETHYST Part A results supported the designation
-
CLE is a serious autoimmune disease that impacts the daily lives of patients and can lead to permanent scarring and disfigurement when left untreated, and has no targeted treatment option
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting, taking place March 27-31. Late-breaking data from Part A (Phase 2) of the AMETHYST Phase 2/3 study will be presented that highlight litifilimab’s effect on cutaneous lupus erythematosus (CLE) disease activity. Litifilimab is a potential first in-class, monoclonal antibody (mAb) targeting blood dendritic cell antigen 2 (BDCA2) and was the first investigational therapy to show positive results in CLE, as shown in the Phase 2 LILAC study. Additional presentations at AAD will provide new insights into measures used to assess the severity of CLE disease activity in both clinical trials and clinical practice.
“The data we are presenting at AAD reflect Biogen’s decades of investment in cutaneous lupus, a disease that extends far beyond the skin, significantly impacting the daily lives and mental health of people living with this disease, and often leading to permanent scarring,” said Diana Gallagher, MD, Senior Vice President and Head of AD, MS and Immunology Development Units at Biogen. “We look forward to sharing the Phase 2 results from AMETHYST that show the potential of litifilimab in CLE. The Phase 3 part of the study, which will further evaluate litifilimab in CLE, is on track and a data readout is expected in 2027.”
Earlier this year, the U.S. Food and Drug Administration granted litifilimab Breakthrough Therapy Designation for CLE. Results from the Phase 2 (Part A) part of the AMETHYST study supported the designation, in addition to the previously presented Phase 2 LILAC study results.
Details of the presentations at AAD are as follows:
Late-Breaking Oral Presentation
-
“Efficacy and Safety of Litifilimab in Cutaneous Lupus Erythematosus (CLE): 24-week results of the Phase 2 Study, AMETHYST Part A” to be presented Saturday, March 28 3:24 PM MT / 5:24 PM ET in Bellco Theatre 3; #79781
Key Posters
-
“A Qualitative Study to Support the Content Validity of the Cutaneous Lupus Activity Investigator’s Global Assessment―Revised (CLA-IGA-R): Clinician Perspectives” on display throughout meeting in Poster Exhibits Center; #71096
-
“Correlation Between CLASI and CLA-IGA-R Among Patients With CLE in a Multi-Center Cross-Sectional Study in the US” on display throughout meeting in Poster Exhibits Center; #75155
About AMETHYST
AMETHYST is a two-part, Phase 2/3 multicenter, double-blind, placebo controlled, randomized study to evaluate the efficacy and safety of litifilimab compared to placebo. The study aims to assess the efficacy of litifilimab in participants with active subacute cutaneous lupus erythematosus (SCLE) and/or chronic cutaneous lupus erythematosus (CCLE) who are refractory or intolerant to antimalarial therapy. The Phase 2 and Phase 3 parts of the study will each be 52 weeks in duration. Participants will be randomized to receive subcutaneous treatment with litifilimab or placebo every four weeks for 20 weeks with an additional dose at Week 2. All participants will receive litifilimab during the 28-week extended treatment period from Weeks 24 to 48. More information on the AMETHYST study (NCT05531565) is available at clinicaltrials.gov.
About Litifilimab (BIIB059)
Litifilimab (known as BIIB059), discovered and developed in-house by Biogen scientists, is a humanized IgG1 monoclonal antibody (mAb) targeting BDCA2 and is being investigated for the potential treatment of systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). BDCA2 is a receptor that is predominantly expressed on a subset of human immune cells called Plasmacytoid Dendritic Cells (pDCs). Binding of litifilimab to BDCA2 has been shown to reduce production of pro-inflammatory molecules by pDCs, including type-I interferon (IFN-I) as well as other cytokines and chemokines.1,2 These pro-inflammatory mediators are thought to play a major role in the pathogenesis of systemic and cutaneous lupus.
Litifilimab is an investigational therapeutic candidate that has not yet been approved by any regulatory authority and its safety and effectiveness have not been established.
About Cutaneous Lupus Erythematosus (CLE)
CLE, a type of lupus, is a serious chronic autoimmune skin disease that can occur with or without systemic manifestations; people with CLE frequently experience symptoms including rash, pain, itch and photosensitivity as well as skin damage that may worsen over time and can include irreversible scarring, alopecia and dyspigmentation that can be disfiguring and substantially impact quality of life.3-6 Currently, there are no approved targeted therapies for CLE and the last drug was approved in the 1950s.
About Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.
References:
-
Furie R, Werth VP, Merola JF, et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest. 2019;129(3):1359-1371. doi:10.1172/JCI124466
-
Pellerin A, Otero K, Czerkowicz JM, et al. Anti-BDCA2 monoclonal antibody inhibits plasmacytoid dendritic cell activation through Fc-dependent and Fc-independent mechanisms. EMBO Mol Med. 2015;7(4):464-476. doi:10.15252/emmm.201404719
-
Drenkard C, Barbour KE, Greenlund KJ, Lim SS. The Burden of Living With Cutaneous Lupus Erythematosus. Front Med (Lausanne). 2022 Aug 8;9:897987. doi: 10.3389/fmed.2022.897987. PMID: 36017007; PMCID: PMC9395260.
-
Ogunsanya ME, Brown CM, Lin D, et al (2018). Understanding the disease burden and unmet needs among patients with cutaneous lupus erythematosus: A qualitative study. Int J Womens Dermatol. 4(3):152-158.
-
Ogunsanya ME, Cho SK, Hudson A, Chong, BF (2019). Validation and reliability of a disease-specific quality of life measure in patients with cutaneous lupus erythematosus. Br J Dermatol. 180(6):1430-1437.
-
Drenkard C, Parker S, Aspey LD, Gordon C, Helmick CG, Bao G, Lim SS. Racial Disparities in the Incidence of Primary Chronic Cutaneous Lupus Erythematosus in the Southeastern US: The Georgia Lupus Registry. Arthritis Care Res (Hoboken). 2019 Jan;71(1):95-103. doi: 10.1002/acr.23578. PMID: 29669194; PMCID: PMC6193862.